Cancer Genomics Laboratory, Department of Biotechnology, School of Chemical and Biotechnology, SASTRA - Deemed University, Thanjavur 613 401, India.
Dana Farber Cancer Institute, Boston, MA 02215, U.S.A.
Biochem Soc Trans. 2020 Dec 18;48(6):2791-2810. doi: 10.1042/BST20200666.
Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype that lacks targeted therapy due to the absence of estrogen, progesterone, and HER2 receptors. Moreover, TNBC was shown to have a poor prognosis, since it involves aggressive phenotypes that confer significant hindrance to therapeutic treatments. Recent state-of-the-art sequencing technologies have shed light on several long non-coding RNAs (lncRNAs), previously thought to have no biological function and were considered as genomic junk. LncRNAs are involved in various physiological as well as pathological conditions, and play a key role in drug resistance, gene expression, and epigenetic regulation. This review mainly focuses on exploring the multifunctional roles of candidate lncRNAs, and their strong association with TNBC development. We also summarise various emerging research findings that establish novel paradigms of lncRNAs function as oncogenes and/or tumor suppressors in TNBC development, suggesting their role as prospective therapeutic targets.
三阴性乳腺癌(TNBC)是一种异质性乳腺癌亚型,由于缺乏雌激素、孕激素和 HER2 受体,因此缺乏靶向治疗。此外,由于 TNBC 具有侵袭性表型,这给治疗带来了很大的阻碍,导致其预后较差。最近的先进测序技术揭示了几种长链非编码 RNA(lncRNA),以前认为它们没有生物学功能,被认为是基因组垃圾。lncRNA 参与各种生理和病理条件,并在药物耐药性、基因表达和表观遗传调控中发挥关键作用。本综述主要探讨候选 lncRNA 的多功能作用及其与 TNBC 发展的强烈关联。我们还总结了各种新出现的研究结果,这些结果确立了 lncRNA 作为癌基因和/或肿瘤抑制因子在 TNBC 发展中的作用的新范例,表明它们可能成为有前途的治疗靶点。